RBC Capital Sticks to Their Hold Rating for Genesis Healthcare

By Austin Angelo

RBC Capital analyst Frank Morgan reiterated a Hold rating on Genesis Healthcare (NYSE: GEN) on September 11 and set a price target of $2. The company’s shares opened today at $1.02, close to its 52-week low of $0.91.

According to TipRanks.com, Morgan is a 5-star analyst with an average return of 10.5% and a 59.2% success rate. Morgan covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Fresenius Medical Care Corp, and Quest Diagnostics Inc.

Genesis Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $4.

The company has a one year high of $4.75 and a one year low of $0.91. Currently, Genesis Healthcare has an average volume of 636.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genesis Healthcare, Inc. is a holding company, which engages in the provision of inpatient services through skilled nursing and assisted and senior living facilities. It also offers rehabilitation and respiratory therapy services. It operates through the following segments: Inpatient Services, Rehabilitation Therapy Services, and Other Services.